Fresenius, DE000FRE5EN2

Fresenius stock: Moody's raises outlook to positive

Published on 11/21/2026 at 12:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Fresenius stock gains a stronger credit signal after Moody's moved its outlook to positive. The Baa3 rating remains unchanged.

Fresenius strengthens its credit profile

  • Moody's changed Fresenius' credit outlook from stable to positive on November 19, 2026.
  • The rating agency affirmed Fresenius' Baa3 investment-grade rating.
  • Fresenius said the revised outlook reflects stronger credit metrics, liquidity and profitability.
Fresenius, DE000FRE5EN2, Illustration mit AI erstellt.

Moody's moved its credit outlook for Fresenius from stable to positive on Thursday, November 19, while affirming the healthcare group's Baa3 rating. The decision gives investors a fresh signal that the company's balance-sheet profile is improving.

In a Fresenius investor-relations release, the company said Moody's cited an improved growth trajectory, higher profitability, stronger credit metrics and solid liquidity. Fresenius also said it had reduced its net leverage ratio to 2.5 times while continuing to invest in growth.

Credit flexibility supports investment plans

Fresenius said the revised outlook increases its strategic flexibility in Medtech, Nutrition and Biopharma. The company highlighted targeted investments, including the acquisition of the remaining 45% stake in mAbxience and a development agreement with WuXi Biologics to expand its biosimilars pipeline.

Moody's change means all three leading rating agencies now have a positive outlook on Fresenius, according to the company. Moody's rates Fresenius Baa3, while S&P rates it BBB and Fitch rates it BBB-.

Fresenius stock traded at 50.86 euros on Lang & Schwarz at 12:25 CET on Saturday, November 21.

Fresenius company facts

  • Company: Fresenius SE & Co. KGaA
  • ISIN: DE000FRE5EN2
  • Home exchange: Frankfurt Stock Exchange
  • Lang & Schwarz quote: 50.86 euros on Saturday, November 21, 2026, at 12:25 CET
  • Moody's rating: Baa3 with a positive outlook

Germany's DAX 40 remains the key market barometer for investors in the Frankfurt-listed healthcare group.

More news and analyses on Fresenius stock

Disclaimer...
en | DE000FRE5EN2 | FRESENIUS | boerse | 70542476 | bgmi